Paradigm CEO Dr. Robert Penny Presents Keynote Address at 2015 ISBER Conference

PHOENIX, and ANN ARBOR, Mich., May 6, 2015 /PRNewswire-USNewswire/ -- Paradigm today announced that Dr. Robert Penny, CEO will give the keynote address at the International Society for Biological and Environmental Repositories (ISBER) 2015 Annual Meeting in Phoenix, AZ at 9:45 AM MST.

Dr. Penny's talk, entitled "Personalized Medicine: The Odyssey" will focus on the historic and critical role biorepositories have had over the past ten years in shaping our personalized medicine revolution.  Furthermore, he will be touching on the clinical promises of the most current molecular platforms used for the generation of patient-specific molecular data that facilitates matching patients to specific anti-tumor agents and clinical trials.

"I am honored to have the opportunity to present my historical perspective on this important topic.  My experiences as co-founder and CEO of The International Genomics Consortium (IGC) leading our Expression Project for Oncology (expO) and serving as Principal Investigator for The Cancer Genome Atlas Project (TCGA) where IGC served as the Biospecimen Core Resource, have been significant to helping shape personalized medicine." noted Dr. Penny, M.D., Ph.D. "These experiences and learnings have been instrumental in assisting and driving our most recent efforts in launching our Paradigm Cancer Diagnostic (PCDx) NGS-based test for cancer patients."

PCDx is a Next-Generation Sequencing (NGS) based diagnostic test that is designed to provide physicians and patients with a more targeted, personalized approach to cancer treatment by identifying the underlying genomic and proteomic alterations of a tumor's DNA, RNA & Protein.

About THE INTERNATIONAL GENOMICS CONSORTIUM

The International Genomics Consortium (IGC) is a non-profit, medical research organization that supports and accelerates the translation of genomic discoveries into medically and scientifically helpful information that physicians, researchers and industry can use for medical management, to validate findings and to make new medical breakthroughs. IGC is a key pioneer in the biosciences industry in Arizona and has played a key leadership role in furthering translational cancer research nationally. IGC envisioned, successfully operationalized and completed the Expression Project for Oncology (expO) whose success was instrumental in assisting to create and launch The Cancer Genome Atlas (TCGA) project. IGC's national role was formally recognized in being awarded three major contracts in TCGA to help lead and operationalize the largest cancer project in the history of Medicine. IGC has deep expertise in collecting, storing, and characterizing tissue samples and clinical data. IGC has become the nation's premier site for biobanking cancer tissues and other biospecimens for groundbreaking genomic research. IGC has contributed to more than 10 papers published in the prestigious journal, Nature.For more information visit http://www.intgen.org

About PARADIGM

Paradigm is a molecular information corporation established to bring cutting-edge diagnostics to cancer patients and clinical trials by providing information about the genomic makeup of the patient's cancer and potential therapies based on the specific characterization of the patient's tumor that can impact the patient's course of treatment. Paradigm's Next-Generation Sequencing based diagnostic test PCDx provides oncologists and patients with more precise information about the specific cancer pathways in the patient and associations between the pathways and the specific drugs available that can affect the cancer to allow for more effective decision-making. The test is driven by supporting data and literature and provides more choices for patient care than currently available on the market. For more information visit http://www.paradigmdx.org.

Photo - http://photos.prnewswire.com/prnh/20150506/214292
Logo - http://photos.prnewswire.com/prnh/20140819/137529

SOURCE Paradigm

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED